Aggressive multimodality treatment for advanced rectal cancer

Ryo Inada, Takeshi Nagasaka, Toshiaki Toshima, Yoshiko Mori, Yoshitaka Kondo, Hiroyuki Kishimoto, Takao Hiraki, Taihei Oshiro, Yukihide Kanemitsu, Toshiyoshi Fujiwara

Research output: Contribution to journalArticle

Abstract

A case of advanced rectal cancer treated by aggressive local and systemic treatment who has survived more than 7 years from initial recurrence is presented. A 55-year-old woman was diagnosed with advanced lower rectal cancer and underwent a low anterior resection with complete removal of all regional lymph nodes and total mesorectal excision. The tumor was diagnosed as a moderately differentiated adenocarcinoma, pStage IIIB (T3, N2a, M0). Twenty-six months after the initial surgery, local recurrence in the pelvis was detected by computed tomography, and total pelvic exenteration with distal sacrectomy (TPES) was performed after systemic chemotherapy with a molecular-targeted drug. Six months after the TPES, multiple lung metastases were detected. Consequently, the patient underwent radiofrequency ablation (RFA) and chemotherapy. The disease has since been controlled for 38 months. As volume control is essential for cancer treatment, it may be important to combine appropriate local therapy with systemic therapy to metastatic or recurrent sites in order to achieve much longer disease control.

Original languageEnglish
Pages (from-to)113-118
Number of pages6
JournalActa Medica Okayama
Volume69
Issue number2
Publication statusPublished - 2015

Fingerprint

Chemotherapy
Rectal Neoplasms
Pelvic Exenteration
Disease control
Oncology
Ablation
Surgery
Tomography
Tumors
Recurrence
Drug Therapy
Therapeutics
Pelvis
Pharmaceutical Preparations
Neoplasms
Adenocarcinoma
Lymph Nodes
Neoplasm Metastasis
Lung

Keywords

  • Colorectal cancer
  • Radiofrequency ablation
  • Recurrence
  • Systemic chemotherapy
  • Total pelvic exenteration

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Aggressive multimodality treatment for advanced rectal cancer. / Inada, Ryo; Nagasaka, Takeshi; Toshima, Toshiaki; Mori, Yoshiko; Kondo, Yoshitaka; Kishimoto, Hiroyuki; Hiraki, Takao; Oshiro, Taihei; Kanemitsu, Yukihide; Fujiwara, Toshiyoshi.

In: Acta Medica Okayama, Vol. 69, No. 2, 2015, p. 113-118.

Research output: Contribution to journalArticle

Inada, R, Nagasaka, T, Toshima, T, Mori, Y, Kondo, Y, Kishimoto, H, Hiraki, T, Oshiro, T, Kanemitsu, Y & Fujiwara, T 2015, 'Aggressive multimodality treatment for advanced rectal cancer', Acta Medica Okayama, vol. 69, no. 2, pp. 113-118.
Inada, Ryo ; Nagasaka, Takeshi ; Toshima, Toshiaki ; Mori, Yoshiko ; Kondo, Yoshitaka ; Kishimoto, Hiroyuki ; Hiraki, Takao ; Oshiro, Taihei ; Kanemitsu, Yukihide ; Fujiwara, Toshiyoshi. / Aggressive multimodality treatment for advanced rectal cancer. In: Acta Medica Okayama. 2015 ; Vol. 69, No. 2. pp. 113-118.
@article{d27078d0ab014cbebeaf5d49a81ebb27,
title = "Aggressive multimodality treatment for advanced rectal cancer",
abstract = "A case of advanced rectal cancer treated by aggressive local and systemic treatment who has survived more than 7 years from initial recurrence is presented. A 55-year-old woman was diagnosed with advanced lower rectal cancer and underwent a low anterior resection with complete removal of all regional lymph nodes and total mesorectal excision. The tumor was diagnosed as a moderately differentiated adenocarcinoma, pStage IIIB (T3, N2a, M0). Twenty-six months after the initial surgery, local recurrence in the pelvis was detected by computed tomography, and total pelvic exenteration with distal sacrectomy (TPES) was performed after systemic chemotherapy with a molecular-targeted drug. Six months after the TPES, multiple lung metastases were detected. Consequently, the patient underwent radiofrequency ablation (RFA) and chemotherapy. The disease has since been controlled for 38 months. As volume control is essential for cancer treatment, it may be important to combine appropriate local therapy with systemic therapy to metastatic or recurrent sites in order to achieve much longer disease control.",
keywords = "Colorectal cancer, Radiofrequency ablation, Recurrence, Systemic chemotherapy, Total pelvic exenteration",
author = "Ryo Inada and Takeshi Nagasaka and Toshiaki Toshima and Yoshiko Mori and Yoshitaka Kondo and Hiroyuki Kishimoto and Takao Hiraki and Taihei Oshiro and Yukihide Kanemitsu and Toshiyoshi Fujiwara",
year = "2015",
language = "English",
volume = "69",
pages = "113--118",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "2",

}

TY - JOUR

T1 - Aggressive multimodality treatment for advanced rectal cancer

AU - Inada, Ryo

AU - Nagasaka, Takeshi

AU - Toshima, Toshiaki

AU - Mori, Yoshiko

AU - Kondo, Yoshitaka

AU - Kishimoto, Hiroyuki

AU - Hiraki, Takao

AU - Oshiro, Taihei

AU - Kanemitsu, Yukihide

AU - Fujiwara, Toshiyoshi

PY - 2015

Y1 - 2015

N2 - A case of advanced rectal cancer treated by aggressive local and systemic treatment who has survived more than 7 years from initial recurrence is presented. A 55-year-old woman was diagnosed with advanced lower rectal cancer and underwent a low anterior resection with complete removal of all regional lymph nodes and total mesorectal excision. The tumor was diagnosed as a moderately differentiated adenocarcinoma, pStage IIIB (T3, N2a, M0). Twenty-six months after the initial surgery, local recurrence in the pelvis was detected by computed tomography, and total pelvic exenteration with distal sacrectomy (TPES) was performed after systemic chemotherapy with a molecular-targeted drug. Six months after the TPES, multiple lung metastases were detected. Consequently, the patient underwent radiofrequency ablation (RFA) and chemotherapy. The disease has since been controlled for 38 months. As volume control is essential for cancer treatment, it may be important to combine appropriate local therapy with systemic therapy to metastatic or recurrent sites in order to achieve much longer disease control.

AB - A case of advanced rectal cancer treated by aggressive local and systemic treatment who has survived more than 7 years from initial recurrence is presented. A 55-year-old woman was diagnosed with advanced lower rectal cancer and underwent a low anterior resection with complete removal of all regional lymph nodes and total mesorectal excision. The tumor was diagnosed as a moderately differentiated adenocarcinoma, pStage IIIB (T3, N2a, M0). Twenty-six months after the initial surgery, local recurrence in the pelvis was detected by computed tomography, and total pelvic exenteration with distal sacrectomy (TPES) was performed after systemic chemotherapy with a molecular-targeted drug. Six months after the TPES, multiple lung metastases were detected. Consequently, the patient underwent radiofrequency ablation (RFA) and chemotherapy. The disease has since been controlled for 38 months. As volume control is essential for cancer treatment, it may be important to combine appropriate local therapy with systemic therapy to metastatic or recurrent sites in order to achieve much longer disease control.

KW - Colorectal cancer

KW - Radiofrequency ablation

KW - Recurrence

KW - Systemic chemotherapy

KW - Total pelvic exenteration

UR - http://www.scopus.com/inward/record.url?scp=84946183137&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946183137&partnerID=8YFLogxK

M3 - Article

VL - 69

SP - 113

EP - 118

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 2

ER -